[Form 4] Charles River Laboratories International, Inc. Insider Trading Activity
Charles River Laboratories EVP Joseph W. LaPlume reported a sale of 400 shares of common stock on 08/07/2025 at $150.04 per share. After the transaction he directly owned 24,916 shares. The filing is a routine Form 4 disclosure recording an officer's change in beneficial ownership and shows no derivative transactions.
Il EVP di Charles River Laboratories, Joseph W. LaPlume, ha dichiarato la vendita di 400 azioni ordinarie il 08/07/2025 al prezzo di $150.04 per azione. Dopo l'operazione 猫 risultato titolare diretto di 24,916 azioni. La comunicazione 猫 un deposito ordinario sul modulo Form 4 che registra una variazione della propriet脿 effettiva di un dirigente e non riporta operazioni su strumenti derivati.
El EVP de Charles River Laboratories, Joseph W. LaPlume, inform贸 la venta de 400 acciones ordinarias el 08/07/2025 a $150.04 por acci贸n. Tras la operaci贸n, pose铆a directamente 24,916 acciones. La presentaci贸n es una divulgaci贸n rutinaria en el Formulario 4 que registra un cambio en la propiedad beneficiaria de un directivo y no muestra transacciones con derivados.
Charles River Laboratories鞚� EVP Joseph W. LaPlume电� 08/07/2025鞐� 氤错喌欤� 400欤�毳� 欤茧嫻 $150.04鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 瓯半灅 頉� 攴傅鐢 歆侅爲 24,916欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞚� 鞝滌稖鞚� 鞛勳洂鞚� 鞁れ唽鞙犼秾 氤�霃欖潉 旮半頃� 鞝曣赴鞝侅澑 Form 4 鞁犼碃搿�, 韺岇儩靸來拡 瓯半灅电� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le EVP de Charles River Laboratories, Joseph W. LaPlume, a d茅clar茅 la vente de 400 actions ordinaires le 08/07/2025 脿 $150.04 l'action. Apr猫s la transaction, il d茅tenait directement 24,916 actions. Le d茅p么t est une divulgation courante au formulaire Form 4 enregistrant un changement de propri茅t茅 b茅n茅ficiaire d'un dirigeant et n'indique aucune op茅ration sur d茅riv茅s.
Der EVP von Charles River Laboratories, Joseph W. LaPlume, meldete den Verkauf von 400 Stammaktien am 08/07/2025 zu $150.04 je Aktie. Nach der Transaktion hielt er direkt 24,916 Aktien. Die Einreichung ist eine routinem盲脽ige Offenlegung im Formular Form 4, die eine 脛nderung des wirtschaftlichen Eigentums eines leitenden Angestellten dokumentiert und keine Gesch盲fte mit Derivaten ausweist.
- None.
- None.
Insights
TL;DR: Small officer sale; limited market impact given remaining direct holdings.
The Form 4 reports a direct sale of 400 common shares at $150.04, leaving the reporting person with 24,916 shares. Table II lists no derivative activity, so this is a straightforward non-derivative disposition. From a trading-impact perspective the transaction size is modest and the disclosure meets Section 16 reporting requirements.
TL;DR: Disclosure complies with Section 16 rules; transaction appears routine for an officer.
Joseph W. LaPlume is identified as an officer (EVP, Corporate Strategy & Development) and the Form 4 records the sale and post-transaction direct ownership. The filing includes a manual signature and an explanation section but contains no indication of a 10b5-1 plan or related derivative transactions in Table II.
Il EVP di Charles River Laboratories, Joseph W. LaPlume, ha dichiarato la vendita di 400 azioni ordinarie il 08/07/2025 al prezzo di $150.04 per azione. Dopo l'operazione 猫 risultato titolare diretto di 24,916 azioni. La comunicazione 猫 un deposito ordinario sul modulo Form 4 che registra una variazione della propriet脿 effettiva di un dirigente e non riporta operazioni su strumenti derivati.
El EVP de Charles River Laboratories, Joseph W. LaPlume, inform贸 la venta de 400 acciones ordinarias el 08/07/2025 a $150.04 por acci贸n. Tras la operaci贸n, pose铆a directamente 24,916 acciones. La presentaci贸n es una divulgaci贸n rutinaria en el Formulario 4 que registra un cambio en la propiedad beneficiaria de un directivo y no muestra transacciones con derivados.
Charles River Laboratories鞚� EVP Joseph W. LaPlume电� 08/07/2025鞐� 氤错喌欤� 400欤�毳� 欤茧嫻 $150.04鞐� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 瓯半灅 頉� 攴傅鐢 歆侅爲 24,916欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞚� 鞝滌稖鞚� 鞛勳洂鞚� 鞁れ唽鞙犼秾 氤�霃欖潉 旮半頃� 鞝曣赴鞝侅澑 Form 4 鞁犼碃搿�, 韺岇儩靸來拡 瓯半灅电� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le EVP de Charles River Laboratories, Joseph W. LaPlume, a d茅clar茅 la vente de 400 actions ordinaires le 08/07/2025 脿 $150.04 l'action. Apr猫s la transaction, il d茅tenait directement 24,916 actions. Le d茅p么t est une divulgation courante au formulaire Form 4 enregistrant un changement de propri茅t茅 b茅n茅ficiaire d'un dirigeant et n'indique aucune op茅ration sur d茅riv茅s.
Der EVP von Charles River Laboratories, Joseph W. LaPlume, meldete den Verkauf von 400 Stammaktien am 08/07/2025 zu $150.04 je Aktie. Nach der Transaktion hielt er direkt 24,916 Aktien. Die Einreichung ist eine routinem盲脽ige Offenlegung im Formular Form 4, die eine 脛nderung des wirtschaftlichen Eigentums eines leitenden Angestellten dokumentiert und keine Gesch盲fte mit Derivaten ausweist.
FAQ
What did Charles River (CRL) insider Joseph LaPlume report on Form 4?
What is Joseph W. LaPlume's role at Charles River (CRL)?
Does the Form 4 show any derivative transactions for CRL?
How many shares did LaPlume own after the reported transaction?
Was the sale reported on Form 4 large relative to the reporting person's holdings?
